Market Overview

Global Nuclear Medicine/Radiopharmaceutical Market to 2024 - A $9.36 Billion Opportunity by 2024 - ResearchAndMarkets.com

Share:

The "Nuclear
Medicine/Radiopharmaceutical Global Market - Forecast To 2024"

report has been added to ResearchAndMarkets.com's
offering.

The nuclear medicine global market is estimated to reach $9,367.8
million by 2024 growing at mid single digit CAGR.

Increased radioisotopes applications, rise in public awareness, use of
SPECT/CT and PET/CT imaging scans, abundance of radiopharmaceuticals,
advancement in imaging technology (hybrid imaging) and alpha therapy
based targeted cancer treatment is boosting nuclear medicine market
growth.

In addition, increasing need in emerging markets, production of
radiopharmaceuticals from cyclotrons, efficient diagnosis and
treatments, emerging radio isotopes and replacement of old/traditional
equipments are the opportunities likely to propel the growth of nuclear
medicine market.

Nuclear medicinal market is classified based on modality into
diagnosis-therapeutics. Diagnostics market held the largest market
revenue in 2017 and is expected grow at single digit CAGR due to
increase in SPECT and PET procedures. The therapeutics segment is
expected to be the fastest growing segment at high double digit CAGR
from 2017 to 2024 due to technological advancements in targeted
treatment of cancers. Potential new radioisotopes in pipeline and
advancement in neurological treatments are the key factors driving the
growth of the therapeutics market.

PET is the fastest growing segment at mid single digit CAGR from 2017 to
2024 due to increase in adoption of cyclotron for production of PET
isotopes increasing its availability.

Therapeutic nuclear medicine market is segmented based on radiation type
into alpha radiation, beta radiation and brachytherapy. Alpha radiation
accounted largest share in 2017 and is the fastest growing market with
projected high double digit CAGR from 2017 to 2024 due to new approval
of Ra-223 based cold kits by FDA and other regulatory agencies.

Nuclear medicine based on end-user is segmented into hospitals,
ambulatory centers, diagnostic centers and others. Hospital accounted
the largest share in 2017 and is the fastest growing market projected
with CAGR of 7.2% from 2017 to 2024 due to readily availability of
cyclotrons for generation of isotope and use of advanced hybrid imaging.

The stable isotope global market is poised to reach $256.9 million by
2024. The Nuclear Medicine market includes stable isotopes which are
classified into isotopes and applications. Isotopes considered are
carbon (C-13), deuterium (D2), oxygen (O-18), nitrogen (N-15), Sulphur
(S-32) and others. Deuterium (D-2) accounted largest share in 2017 and
is the fastest growing market with projected low single digit CAGR
growth from 2017 to 2024 due to use of deuterium as dietary supplement
of deuterium-depleted water which helps to extend survival rate of lung
cancer patient via exerting anticancer effect and modification of
deuterium leads to development of novel, highly differentiated drugs
which have therapeutic applications in diabetic nephropathy, hot
flashes, spasticity, neuropathic pain and multiple melanoma.

Market Dynamics

Drivers & Opportunities

  • Increased Applications of Radiopharmaceuticals
  • Rise in Public Awareness
  • Usage of Hybrid Imaging
  • Technological Advancements
  • Increasing Needs in Emerging Markets
  • Production of Radiopharmaceuticals from Cyclotrons
  • Efficient Diagnosis and Treatments

Restraints & Threats

  • Shorter Half-Life of Radiopharmaceuticals
  • High Cost and Supply Shortage of Isotopes
  • Radio Toxicity
  • Shortage of Qualified Technicians
  • Regulatory Issues
  • Threat from Traditional/Alternative Diagnostic Procedures
  • Huge Capital Investment

Problem Areas

  • Closure of Reactors

Winning Imperatives

  • Availability of Technetium

Key Topics Covered

1. Executive Summary

2. Introduction

3. Market Analysis

4. Nuclear Medicine Global Market, By Modality

5. Nuclear Medicine Global Market, By End-Users

6. Stable Isotopes

7. Regional Analysis

8. Competitive Landscape

9. Major Player Profiles

  • 13 C Molecular
  • Actinium Pharmaceuticals, Inc.
  • Advanced Nuclear Medicine Ingredients
  • Alpha Tau Medical
  • Arronax Cyclotron
  • Beijing Zhibo Biomedical Technology Co. Ltd.
  • Best Medical International, Inc.
  • Blue Earth Diagnostics Limited
  • Bracco Group
  • BTG International Ltd.
  • BV Cyclotron VU
  • Cardinal Health Inc.
  • Cellectar Biosciences
  • Clarity's Pharmaceuticals
  • Curium Pharma
  • Eckert & Ziegler Strahlen
  • Eli Lilly & Co (Avid Radiopharmaceuticals)
  • Eurisotop
  • Fujifilm Corporation
  • GE Company
  • Institute of Isotopes
  • International Isotopes Inc.
  • Iso-Analytical Ltd.
  • IsoAid LLC
  • Isoflex Isotope
  • Isorad Ltd.
  • Isoray Medical Inc.
  • IsoSciences, LLC
  • iThemba labs
  • Pars Isotope
  • Solcom Limited
  • Theragenics Corporation
  • Theragnostics Ltd.
  • Tianjin Seeds Biological Pharmacy Co. Ltd
  • and many more...

For more information about this report visit https://www.researchandmarkets.com/research/qpjlnl/global_nuclear?w=4

View Comments and Join the Discussion!